Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

Por Calvo, E., Moreno, V., Flynn, M., Holgado, E., Olmedo, M. E., Lopez Criado, M. P., Kahatt, C., Lopez-Vilariño, J. A., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Soto Matos-Pita, A., Forster, M.
Publicado no Ann Oncol (2017)

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

Por Yap, T A, Cortes-Funes, H, Shaw, H, Rodriguez, R, Olmos, D, Lal, R, Fong, P C, Tan, D S, Harris, D, Capdevila, J, Coronado, C, Alfaro, V, Soto-Matos, A, Fernández-Teruel, C, Siguero, M, Tabernero, J M, Paz-Ares, L, de Bono, J S, López-Martin, J A
Publicado em 2012

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

Por Poveda, A., del Campo, J. M., Ray-Coquard, I., Alexandre, J., Provansal, M., Guerra Alía, E. M., Casado, A., Gonzalez-Martin, A., Fernández, C., Rodriguez, I., Soto, A., Kahatt, C., Fernández Teruel, C., Galmarini, C. M., Pérez de la Haza, A., Bohan, P., Berton-Rigaud, D.
Publicado no Ann Oncol (2017)